Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bao Ho

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Acta Odontologica Scandinavica|April 5, 2014
Studies of genes involved in craniofacial development and tumorigenesis: FGF3 contributes to isolated oral clefts and may interact with PAX9Erika C Küchler, Ticiana M Sabóia, Thays C Vieira, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 18, 2022
The PRIMARY Score: Using Intraprostatic <sup>68</sup>Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer DiagnosisLouise Emmett, Nathan Papa, James Buteau, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 25, 2022
Evaluation of <sup>177</sup>Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective <sup>177</sup>Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)Sarennya Pathmanandavel, Megan Crumbaker, Bao Ho, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 25, 2017
The Impact of <sup>68</sup>Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter StudyPaul J Roach, Roslyn Francis, Louise Emmett, et al.
BJU International|April 29, 2022
Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groupsMatthew J Roberts, Mark D Chatfield, George Hruby, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 24, 2019
The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of <sup>18</sup>F-Fluoromethylcholine or <sup>68</sup>Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical ProstatectomyUr Metser, Sue Chua, Bao Ho, et al.
BJU International|November 13, 2022
Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancerPaul Doan, William Counter, Nathan Papa, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|June 8, 2023
Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trialSamuel Tremblay, Mofarej Alhogbani, Andrew Weickhardt, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 10, 2022
<sup>177</sup>Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing <sup>177</sup>Lu-PSMA-I&T TherapyNikeith John, Sarennya Pathmanandavel, Megan Crumbaker, et al.
BJU International|July 10, 2019
Diagnostic accuracy of <sup>68</sup> Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of <sup>68</sup> Ga-PSMA PET to mpMRIMatthijs J Scheltema, John I Chang, Phillip D Stricker, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Acta Odontologica Scandinavica|April 5, 2014
Studies of genes involved in craniofacial development and tumorigenesis: FGF3 contributes to isolated oral clefts and may interact with PAX9Erika C Küchler, Ticiana M Sabóia, Thays C Vieira, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 18, 2022
The PRIMARY Score: Using Intraprostatic <sup>68</sup>Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer DiagnosisLouise Emmett, Nathan Papa, James Buteau, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 25, 2022
Evaluation of <sup>177</sup>Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective <sup>177</sup>Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)Sarennya Pathmanandavel, Megan Crumbaker, Bao Ho, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 25, 2017
The Impact of <sup>68</sup>Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter StudyPaul J Roach, Roslyn Francis, Louise Emmett, et al.
BJU International|April 29, 2022
Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groupsMatthew J Roberts, Mark D Chatfield, George Hruby, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 24, 2019
The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of <sup>18</sup>F-Fluoromethylcholine or <sup>68</sup>Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical ProstatectomyUr Metser, Sue Chua, Bao Ho, et al.
BJU International|November 13, 2022
Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancerPaul Doan, William Counter, Nathan Papa, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|June 8, 2023
Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trialSamuel Tremblay, Mofarej Alhogbani, Andrew Weickhardt, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 10, 2022
<sup>177</sup>Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing <sup>177</sup>Lu-PSMA-I&T TherapyNikeith John, Sarennya Pathmanandavel, Megan Crumbaker, et al.
BJU International|July 10, 2019
Diagnostic accuracy of <sup>68</sup> Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of <sup>68</sup> Ga-PSMA PET to mpMRIMatthijs J Scheltema, John I Chang, Phillip D Stricker, et al.
Pageof 7